Integrated Filing — IndAS



General information about company

Scrip Code 506820
NSE Symbol ASTRAZEN
MSEI Symbol NA
ISIN INE203A01020
Name of company ASTRAZENECA PHARMA INDIA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 10-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-08-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Healthcare
Start date and time of board meeting 10-08-2026   11:15:00
End date and time of board meeting 10-08-2026   13:40:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
1-The Statements of financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the “Act”) [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. 2-The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. 3-During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company’s manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and the Company is now in the process of sale of assets related to the manufacturing site. 4-The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year i.e 31 March 2026 and the published unaudited year-to-date figures up to the third quarter of the respective financial year i.e 31 December 2025 which were subjected to limited review by the statutory auditors. 5-Exceptional items for the quarter ended 30 June 2026 , 31 March 2026 and 30 June 2025 and year ended 31 March 2026 consists of expenses related to closure of the manufacturing site. (Refer note 3 above) 6-Subsequent to quarter end, the Company received an order from National Pharmaceutical Pricing Authority to deposit an amount of Rs.1,486.58 Million (including interest thereon) alleging overcharging of a combination respiratory drug sold during the period between May 2016 to November 2025. Based on evaluation, Management is of the view that there are reasonable grounds to challenge the same. Accordingly, management has assessed and concluded this matter as a contingent liability and no provision has been recorded in these financial results. 7-Subsequent to the end of the quarter, the Company has received from a third party an amount of Rs. 100 million, recognised as other income in July 2026, towards compensation for commercial losses. Based on its assessment in accordance with Ind AS, the Company has determined that the aforesaid receipt constitutes a non-adjusting event after the reporting period. Accordingly, no adjustment has been made to these financial results. 8-This Statement of unaudited financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 10 August 2026. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter ended 30 June 2026.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 68,279.00 68,279.00
Other income 923.00 923.00
Total income 69,202.00 69,202.00
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 30,462.00 30,462.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 14,259.00 14,259.00
(d) Employee benefit expense 7,916.00 7,916.00
(e) Finance costs 195.00 195.00
(f) Depreciation, depletion and amortisation expense 523.00 523.00
(f) Other Expenses
1 Allowance for expected credit loss (net) 260.00 260.00
2 Selling, marketing and distribution expense 3,075.00 3,075.00
3 Others 7,413.00 7,413.00
Total other expenses 10,748.00 10,748.00
Total expenses 64,103.00 64,103.00
3 Total profit before exceptional items and tax 5,099.00 5,099.00
4 Exceptional items (24.00) (24.00)
5 Total profit before tax 5,075.00 5,075.00
6 Tax expense
7 Current tax 1,087.00 1,087.00
8 Deferred tax 195.00 195.00
9 Total tax expenses 1,282.00 1,282.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 3,793.00 3,793.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 3,793.00 3,793.00
17 Other comprehensive income net of taxes (30.00) (30.00)
18 Total Comprehensive Income for the period 3,763.00 3,763.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 500.00 500.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 15.17 15.17
Diluted earnings (loss) per share from continuing operations 0 0
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 15.17 15.17
Diluted earnings (loss) per share from continuing and discontinued operations 0 0
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1 The Statements of financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the “Act”) [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. 3 During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company’s manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and the Company is now in the process of sale of assets related to the manufacturing site. 4 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year i.e 31 March 2026 and the published unaudited year-to-date figures up to the third quarter of the respective financial year i.e 31 December 2025 which were subjected to limited review by the statutory auditors. 5 Exceptional items for the quarter ended 30 June 2026 , 31 March 2026 and 30 June 2025 and year ended 31 March 2026 consists of expenses related to closure of the manufacturing site. (Refer note 3 above). 6 Subsequent to quarter end, the Company received an order from National Pharmaceutical Pricing Authority to deposit an amount of Rs.1,486.58 Million (including interest thereon) alleging overcharging of a combination respiratory drug sold during the period between May 2016 to November 2025. Based on evaluation, Management is of the view that there are reasonable grounds to challenge the same. Accordingly, management has assessed and concluded this matter as a contingent liability and no provision has been recorded in these financial results. 7 Subsequent to the end of the quarter, the Company has received from a third party an amount of Rs. 100 million, recognised as other income in July 2026, towards compensation for commercial losses. Based on its assessment in accordance with Ind AS, the Company has determined that the aforesaid receipt constitutes a non-adjusting event after the reporting period. Accordingly, no adjustment has been made to these financial results. 8 This Statement of unaudited financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 10 August 2026. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter ended 30 June 2026. By Order of the Board of Directors For AstraZeneca Pharma India Limited Place: Bengaluru Praveen Rao Akkinepally Date: 10 August 2026 Managing Director



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gains / (losses) on post employment benefit obligations (40.00) (40.00)
Total Amount of items that will not be reclassified to profit and loss (40.00)
2 Income tax relating to items that will not be reclassified to profit or loss (10.00) (10.00)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (30.00) (30.00)